Leading a new approach to treat neurodegenerative diseases
nLife Therapeutics is a biotechnology company leading the discovery and development of oligonucleotide therapies for the treatment of central nervous system disorders. This therapy, based on antisense and RNAi-based technology, modulates the expression of disease-associated genes leading to a therapeutic outcome.
Parkinson’s Disease is nLife’s main Program with a candidate molecule in pre-clinical development, including studies in non-human primates.
nLife is based in Spain and counts with an interdisciplinary team of 19 professionals experienced in biotech/pharmaceutical settings.
Proprietary Oligonucleotide Delivery Technology
nLife has developed an unique proprietary technology to direct therapeutic oligonucleotides to selected groups of neurons. This is achieved by chemically conjugating the oligonucleotide with a ligand that has high affinity for a transporter or receptor existent in the target neuron. This targeted technology assures the specific delivery of the therapeutic oligonucleotide, and reduces side effects. Furthermore, the conjugated oligonucleotides reach selectively the brain through intranasal administration, hence bypassing the blood-brain-barrier non-invasively.
In-House Capabilities and Facilities – From Discovery to Development
nLife designs, synthetizes and validates its own molecules in-house. The chemical synthesis, in vitro biomolecular characterization and in vivo pharmacology are performed in its HQ and R&D facilities of the Health Science Technologic Park in Granada. Moreover, nLife has the expertise to manage internally the Regulatory Development of the candidate molecule in its Barcelona’s office.
H2020 Research Collaborations
nLife is offering its unique expertise in oligonucleotide therapies for CNS diseases and is seeking R&D partners for the H2020 framework program. nLife is interested in forming part of consortia with industry or academia in the following topics:
• Central Nervous System (CNS)
• Gene modulation to unveil neuronal circuits
• Target validation
• Gene therapy (CRISPR/Cas9) for neuronal gene editing
• Parkinson’s Disease
• Duchene Muscular Dystrophy (DMD)
• Amyotrophic Lateral Sclerosis (ALS)
• Spinal Muscular Atrophy (SMA)